natgillin/translations-raw huggingface dataset:
Vaccinen gives til kaniner fra alderen 30 dage som en enkelt injektion under huden på siden af brystet.
The vaccine is given to rabbits from 30 days of age as a single injection under the skin of the side of the chest.
Vaccinen gives til slagtesvin fra 3-ugers alderen som en enkelt injektion i huden på siden af halsen, på ryggen eller i bagbenet.
The vaccine is given to fattening pigs from three weeks of age as a single injection into the skin at the side of the neck, along the back or in the hind leg.
Vaccinen gives til svin fra 3-ugers alderen som en enkelt injektion i nakkemuskulaturen bag øret.
The vaccine is given to pigs from three weeks of age as a single injection into the muscle in the neck behind the ear.
Vaccinen gives til svin fra 3-ugers alderen som en enkelt injektion i nakkemuskulaturen.
The vaccine is given to pigs from three weeks of age as a single injection into the neck muscle.
Vaccinen gives til unge dyr fra de er 2,5 måned gamle som to subkutane injektioner givet med tre ugers mellemrum.
The vaccine is given to young animals from two and a half months of age onwards as two injections administered subcutaneously with an interval of three weeks.
Vaccinen gives ved indsprøjtning i lårmusklen hos spædbørn eller i overarmsmusklen hos mindre børn.
The vaccine is given by injection into the thigh muscle in infants, or into the upper arm muscle in young children.
Vaccinen gives ved injektion i en muskel.
The vaccine is given by injection into a muscle.
Vaccinen har sat sig på overfladen (er "adsorberet") på aluminiumforbindelser.
The vaccine is ‘adsorbed’ on aluminium compounds.
Vaccinen hjælper med at dulme sygdommenes symptomer.
The vaccine helps to reduce the symptoms of the diseases.
Vaccinen hjælper med at reducere symptomerne på sygdommene og med at reducere virusudskillelse i tilfælde af calicivirus-infektion.
The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection.
Vaccinen hjælper med at reducere symptomerne på sygdommene.
The vaccine helps to reduce the symptoms of the diseases.
Vaccinen indeholder "overfladeantigen" fra tre forskellige stammer (typer) af influenzavirus: A/California/7/2009 (H1N1)pdm09-lignende stamme, A/Switzerland/9715293/2013 (H3N2)–lignende stamme og B/Phuket/3073/2013-lignende stamme.
The vaccine contains ‘surface antigens’ from three different strains (types) of influenza (flu) virus: A/California/7/2009 (H1N1)pdm09-like strain; A/Switzerland/9715293/2013 (H3N2)–like strain; and B/Phuket/3073/2013-like strain.
Vaccinen indeholder 11,3 mikrogram thiomersal.
The vaccine contains 11.3 micrograms thiomersal.
Vaccinen indeholder 5 levende rotavirus-stammer.
The vaccine contains five types of live rotavirus strains.
Vaccinen indeholder desuden "adjuvanser" (aluminiumhydroxid og saponin) for at forstærke immunresponsen.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to enhance the immune response.
Vaccinen indeholder desuden "adjuvanser" (aluminiumhydroxid og saponin), der forstærker immunreaktionen.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to enhance the immune response.
Vaccinen indeholder desuden "adjuvanser" (aluminiumhydroxid og saponin), der forstærker immunresponset.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to enhance the immune response.
Vaccinen indeholder desuden "adjuvanser" for at forstærke responsen.
The vaccine also contains ‘adjuvants’ to stimulate a better response.
Vaccinen indeholder desuden en aluminiumholdig forbindelse (et "adjuvans"), der forstærker immunreaktionen.
The vaccine also contains an ‘adjuvant’, a compound containing aluminium to stimulate a better response.
Vaccinen indeholder desuden en »adjuvans« (en aluminiumholdig forbindelse), som giver en bedre respons.
The vaccine also contains an ‘adjuvant’ (a compound containing aluminium) to stimulate a better response.
Vaccinen indeholder desuden et "adjuvans" (en aluminiumholdig forbindelse), der forstærker immun- responsen.
The vaccine also contains an ‘adjuvant’ (a compound containing aluminium) to stimulate a better response.
Vaccinen indeholder desuden et "adjuvans" (et aluminiumholdigt stof), der forstærker immunresponsens beskyttende virkning.
The vaccine also contains an ‘adjuvant’ (a compound containing aluminium) to stimulate a better protective immune response.
Vaccinen indeholder desuden et "adjuvans" (flydende paraffin), der forstærker immunresponset.
The vaccine also contains an ‘adjuvant’ (liquid paraffin) to stimulate a better response.
Vaccinen indeholder desuden et "adjuvans" (mineralsk olie), der forstærker immunresponset.
The vaccine also contains an ‘adjuvant’ (mineral oil) to stimulate a better response.
Vaccinen indeholder desuden et "adjuvans", der forstærker immunforsvaret.
The vaccine also contains an ‘adjuvant’ to enhance the immune response.
Vaccinen indeholder desuden et "adjuvans", der forstærker immunresponset.
The vaccine also contains an ‘adjuvant’ to stimulate a better immune response.
Vaccinen indeholder desuden et "adjuvans", der styrker immunreaktionen.
The vaccine also contains an ‘adjuvant’ to enhance the immune response.
Vaccinen indeholder desuden et "adjuvans", som giver en bedre immunrespons.
The vaccine also contains an ‘adjuvant’ to enhance the immune response.
Vaccinen indeholder desuden »adjuvanser« (aluminiumhydroxid og saponin) for at forstærke responsen.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to stimulate a better response.
Vaccinen indeholder dræbt bluetonguevirus med aluminiumhydroxid og saponin som adjuvans.
The vaccine contains inactivated Bluetongue Virus with aluminium hydroxide and saponin adjuvants.
Vaccinen indeholder dræbt bluetonguevirus serotype 1 med aluminiumhydroxid og saponin som adjuvans.
The vaccine contains inactivated Bluetongue Virus Serotype 1 with aluminium hydroxide and saponin adjuvants.
Vaccinen indeholder dræbt bluetonguevirus serotype 2 og 4 med aluminiumhydroxid og saponin som adjuvans.
The vaccine contains inactivated bluetongue virus serotypes 2 and 4 with aluminium hydroxide and saponin adjuvants.
Vaccinen indeholder dræbt bluetonguevirus serotype 8 med aluminiumhydroxid og saponin som adjuvans.
The vaccine contains inactivated Bluetongue virus serotype 8 with aluminium hydroxide and saponin adjuvants.
Vaccinen indeholder en "adjuvans" (en olieholdig forbindelse), som giver en bedre immunrespons.
The vaccine contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Vaccinen indeholder en influenzavirusstamme kaldet ‘A/VietNam/1194/2004 NIBRG 14’ (H5N1).
The vaccine contains a flu strain called ‘A/VietNam/1194/2004 NIBRG 14’ (H5N1).
Vaccinen indeholder en influenzavirusstamme kaldet ”A/Indonesia/05/2005 PR8- IBCDC-RG2” (H5N1).
The vaccine contains a flu strain called ‘A/Indonesia/05/2005 PR8-IBCDC- RG2’ (H5N1).
Vaccinen indeholder en influenzavirusstamme kaldet ”A/VietNam/1194/2004 NIBRG-14” (H5N1).
The vaccine contains a flu strain called ‘A/VietNam/1194/2004 NIBRG-14’ (H5N1).
Vaccinen indeholder en ‘adjuvans’ (en olieholdig forbindelse), som giver en bedre immunrespons.
The vaccine contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Vaccinen indeholder en ’adjuvans’ (AS03) for at opnå en bedre virkning.
The vaccine contains an ‘adjuvant’ AS03 to stimulate a better response.
Vaccinen indeholder en ’adjuvans’ AS03.
The vaccine contains an ‘adjuvant’ AS03.
Vaccinen indeholder en “adjuvans” AS03.
The vaccine contains an ‘adjuvant’ AS03.
Vaccinen indeholder en ”adjuvans” AS03.
The vaccine contains an ‘adjuvant’ AS03.
Vaccinen indeholder endvidere et hjælpestof (flydende paraffin) for at fremme en bedre reaktion.
The vaccine also contains an ‘adjuvant’ (liquid paraffin) to stimulate a better response.
Vaccinen indeholder et adjuvans til forbedring af immunresponsen.
The vaccine also contains an ‘adjuvant’ to enhance the immune response.
Vaccinen indeholder et inaktiveret, rekombinant kimært porcint circovirus type 1 med porcint circovirus type 2 ORF2-protein og inaktiveret Mycoplasma hyopneumoniae.
The vaccine contains an inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein and inactivated Mycoplasma hyopneumoniae.
Vaccinen indeholder et ‘adjuvans’ (et hjælpestof, som indeholder squalen) for at stimulere en bedre reaktion.
The vaccine contains an ‘adjuvant’ (a compound containing squalene) to stimulate a better response.
Vaccinen indeholder et ‘adjuvans’ (MF59C.1), der skal stimulere en bedre reaktion.
The vaccine contains an ‘adjuvant’ (MF59C.1) to stimulate a better response.
Vaccinen indeholder fase-I Coxiella burnetii som aktiv substans til induktion af aktiv immunitet mod Q- feber i kvæg og geder.
The vaccine contains phase I Coxiella burnetii as active ingredient inducing active immunity against Q fever in cattle and goats.
Vaccinen indeholder fase-I Coxiella burnetii som aktiv substans, der inducerer aktiv immunitet mod Q- feber i kvæg og geder.
The vaccine contains phase I Coxiella burnetii as active ingredient inducing active immunity against Q fever in cattle and goats.
Vaccinen indeholder hele dræbte V. cholerae O1 -bakterier og den rekombinante non-toksiske B- subenhed af koleratoksinet (CTB).
The vaccine contains killed whole V. cholerae O1 bacteria and the recombinant non-toxic B-subunit of the cholera toxin (CTB).
Vaccinen indeholder ikke levende bakterier eller virus, og den kan ikke give nogen af de smitsomme sygdomme, som den beskytter imod.
The vaccine does not contain any live bacteria or viruses and it cannot cause any of the infectious diseases against which it protects.
Vaccinen indeholder ikke levende bakterier eller virusser, og den kan ikke give nogen af de smitsomme sygdomme, som den beskytter imod.
The vaccine does not contain any live bacteria or viruses and it cannot cause any of the infectious diseases against which it protects.
Vaccinen indeholder ikke noget levende PCV2, og antigenet kan ikke formere sig i dyret.
The vaccine does not contain any live PCV2 and the antigen cannot replicate in the animal.
Vaccinen indeholder inaktiveret bluetonguevirus serotype 8 med aluminiumhydroxid og saponin som adjuvans.
The vaccine contains inactivated bluetongue virus serotype 8 with aluminium hydroxide and saponin adjuvants.
Vaccinen indeholder også "adjuvanser" (aluminiumhydroxid og saponin), som giver en bedre immunrespons.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) that enhance the response of the immune system.
Vaccinen indeholder også "adjuvanser" (aluminiumhydroxid og saponin), som giver en bedre immunrespons.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to enhance the immune response.
Vaccinen indeholder også 'adjuvanser' (et aluminiumholdigt stof, mineralolie, en emulgator og en detergent), der har til formål at stimulere en bedre respons.
The vaccine also contains ‘adjuvants’ (a compound containing aluminium as well as mineral oil, an emulsifier and a detergent) to stimulate a better response.
Vaccinen indeholder også en adjuvans (et stof, som kaldes saponin), der har til formål at stimulere en bedre respons.
The vaccine also contains an ‘adjuvant’ (a compound called saponin) to stimulate a better response.
Vaccinen indeholder også en »adjuvans« (en olieholdig forbindelse), som giver en bedre immunrespons.
The vaccine also contains an ‘adjuvant’ (a compound containing oil) to stimulate a better response.
Vaccinen indeholder også et ”adjuvans” (en olieholdig forbindelse), som giver en bedre immunrespons.
The vaccine also contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Vaccinen indeholder også “adjuvanser” for at forstærke immunresponsen.
The vaccine also contains ‘adjuvants’ to stimulate a better response.
Vaccinen indeholder også ”adjuvanser” (aluminiumhydroxid og saponin), som forstærker immunsystemets respons.
The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to stimulate a better reaction by the immune system.
Vaccinen indeholder små mængder af et protein fra PCV2 og hele Mycoplasma hyopneumoniae bakterier, som er dræbt (inaktiveret), så de ikke forårsager sygdom.
The vaccine contains small amounts of a protein from PCV2 and whole Mycoplasma hyopneumoniae bacteria that have been killed (inactivated) so that they do not cause disease.
Vaccinen indeholder to stoffer, ”MPL” (et ikke-toksisk oprenset lipid fra bakterier) og ”aluminiumphosphat”.
Fendrix contains two things called “MPL” (a non-toxic purified fat derivative from bacteria) and “aluminium phosphate”.
Vaccinen indeholder visse dele af H5N1-virusset.
This vaccine contains some parts of the H5N1 virus.
Vaccinen inducerer aktiv immunitet og et serologisk respons over for infektiøs bursal sygdom og Marek’s sygdom hos kyllinger.
The vaccine induces an active immunity and a serological response against Infectious Bursal Disease and Marek’s Disease in chickens.
Vaccinen inducerer en aktiv og specifik immunitet mod parvovirus fra moskusænder og Derszy’s sygdom i de vaccinerede fugle.
It induces an active and specific immunity against Muscovy duck parvovirosis and Derzsy’s disease in the vaccinated birds.
Vaccinen inducerer en aktiv og specifik immunitet mod parvovirus fra moskusænder og Derzsy’s sygdom i de vaccinerede fugle.
It induces an active and specific immunity against Muscovy duck parvovirosis and Derzsy’s disease in the vaccinated birds.
Vaccinen inducerer specifikke humorale antistoffer mod hepatitis B virus overflade-antigen (anti- HBsAg).
The vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg).
Vaccinen kan anvendes sammen med tetanusserum fra Intervet til behandling af tilskadekomne heste, der ikke er blevet immuniseret mod stivkrampe.
The vaccine can be used together with Tetanus-Serum from Intervet for treatment of injured horses that have not been immunised against tetanus.
Vaccinen kan anvendes sammen med tetanusserum til behandling af tilskadekomne heste, der ikke er blevet immuniseret mod stivkrampe.
The vaccine can be used together with Tetanus-Serum for treatment of injured horses that have not been immunised against tetanus.
Vaccinen kan anvendes til dyr fra 2-ugers alderen ved fravær af maternelle antistoffer over for IBR-virus, eller fra 3-måneders alderen ved tilstedeværelse af maternelle antistoffer.
For use in animals from the age of 2 weeks in the absence of maternally derived antibodies against IBR virus or from the age of 3 months in the presence of maternally derived antibodies.
Vaccinen kan gives når du/dit barn er blevet rask igen.
The vaccine can be given after you have recovered.
Vaccinen kan gives uden hensyntagen til indtagelse af føde, væske eller modermælk.
The vaccine can be given without regard to food, liquid, or breast milk.
Vaccinen kan ikke forårsage de sygdomme, som den beskytter mod.
The vaccine cannot cause the diseases that it protects your child from.
Vaccinen kan indgives med automatsprøjte.
The vaccine may be injected by an automatic syringe.
Vaccinen kan kun forventes atbeskytte mod influenza forårsaget af A/California/07/2009 (H1N1)v-lignende stammer.
The vaccine can only be expected to protect against influenza caused by A/California/07/2009 (H1N1)v-like strains.
Vaccinen kan spredes til fugle,der er i kontakt med hinanden.
The vaccine strain may spread to in-contact birds.
Vaccinen kan tages ud af køleskabet højst 12 timer før brug og opbevares ved en temperatur, der ikke overstiger 25 °C. Hvis vaccinen ikke er blevet anvendt i løbet af denne 12-timers periode, skal den bortskaffes.
Before use, the vaccine may be taken out of the refrigerator, without being replaced, for a maximum period of 12 hours at a temperature not above 25°C. If the vaccine has not been used after this 12-hour period, it should be disposed of.
Vaccinen kan tages ud af køleskabet højst 12 timer før brug og opbevares ved en temperatur, der ikke overstiger 25°C. Hvis vaccinen ikke er blevet anvendt i løbet af denne 12-timers periode, skal den bortskaffes.
Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 12 hours at a temperature not above 25°C. If the vaccine has not been used after this 12 hour period, it should be discarded.
Vaccinen leveres i en type I (Ph.
The vaccine is supplied in type I (Ph.
Vaccinen leveres i hætteglas Type I engangssprøjte, der indeholder en dosis (1 ml) vaccine.
Single dose disposable Type I glass syringes containing one dose (l ml) of vaccine.
Vaccinen leveres i hætteglas Type I. Hætteglassene med solvens er lukket med en prop af chlorbutylgummi og et aluminiumlåg.
Type 1 glass vial containing 1 ml of solvent closed with a chlorobutyl rubber stopper and aluminium cap.
Vaccinen leveres i hætteglas Type I. Hætteglassene med solvens er lukket med en prop af chlorbutylgummi og et aluminiumlåg.
Type I glass vial containing 1 ml of solvent closed with a chlorobutyl rubber stopper and aluminium cap.
Vaccinen leveres som frysetørret pellet i hætteglas eller som frysetørret kugler i bægre.
The vaccine may be delivered as a freeze-dried cake in a glass vial or as freeze-dried spheres in cups.
Vaccinen medvirker til at reducere symptomerne ved disse sygdomme.
The vaccine helps to reduce the signs of these diseases.
Vaccinen må aldrig gives i en blodåre (vene).
The vaccine should never be given into a vein.
Vaccinen må aldrig gives ind i en blodåre eller lige under huden.
The vaccine should never be given into a blood vessel or into the skin.
Vaccinen må ikke indsprøjtes.
Do not inject.
Vaccinen må ikke injiceres.
Do not inject.
Vaccinen opfylder WHO’s anbefalinger for den nordlige halvkugle samt EU’s bestemmelser for sæsonen 2015/2016.
The vaccine complies with the WHO recommendation (northern hemisphere) and EU decision for the 2015/2016 season.
Vaccinen rekonstitueres ved at tilsætte hele indholdet i hætteglasset indeholdende DTPa-HBV-IPV- suspension, ved hjælp af en sprøjte, til hætteglasset indeholdende pulveret.
The vaccine is reconstituted by adding the entire contents of the vial containing the DTPa-HBV-IPV suspension by means of a syringe to the vial containing the powder.
Vaccinen rekonstitueres ved at tilsætte hele indholdet i hætteglasset indeholdende DTPa-HBV-IPV- suspensionen ved hjælp af en injektionssprøjte til hætteglasset indeholdende pulveret.
The vaccine is reconstituted by adding the contents of the vial containing the DTPa-HBV-IPV suspension by means of a syringe to the vial containing the powder.
Vaccinen skal administreres i overensstemmelse med den anbefalede dosis (se pkt.
The vaccine should be administered in accordance with the recommended posology (see section 3.
Vaccinen skal administreres straks efter anbrud.
After first opening of the multidose vial, immediate use is recommended.
Vaccinen skal anvendes umiddelbart efter anbrud.
The vaccine should be used immediately after opening.
Vaccinen skal blandes med bufferopløsning inden brug.
Mix vaccine with buffer before use.
Vaccinen skal blandes med bufferopløsningen som beskrevet i denne indlægsseddel.
Make sure to mix the vaccine with buffer solution as described in this leaflet.
Vaccinen skal bortskaffes, hvis den ikke anvendes inden for 30 minutter.
Discard if reconstituted vaccine is not used within 30 minutes.
Vaccinen skal bruges som leveret.
The vaccine should be used as supplied.
Vaccinen skal drikkes inden for 2 timer efter opblanding med bufferopløsningen.
Drink the vaccine within 2 hours after mixing with the buffer solution.
Vaccinen skal gives tidligt om morgenen, da fuglene fortrinsvis drikker på dette tidspunkt, eller på varme dage under en sval periode af dagen.
The vaccine should be given in the early morning as this is the main period of water intake or during the cool period on a hot day.
Vaccinen skal have stuetemperatur, inden den administreres.
The vaccine should be allowed to reach room temperature before use.
Vaccinen skal helst injiceres intramuskulært i deltoideus eller i det anterolaterale lår (afhængigt af muskelmasse).
Immunisation should be carried out by intramuscular injection preferably into the deltoid muscle or anterolateral thigh (depending on the muscle mass).
Vaccinen skal injiceres intramuskulært (i.m.) eller subkutant (s.c.).
The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).
Vaccinen skal injiceres intramuskulært i musculus deltoideus eller anterolateralt i låret (afhængigt af muskelmasse).
Immunisation should be carried out by intramuscular injection into the deltoid muscle or anterolateral thigh (depending on the muscle mass)..
Vaccinen skal inspiceres visuelt for fremmede partikler eller misfarvning inden administration.
The vaccine should be inspected visually in order to detect any appearance of precipitate or discolouring of the content prior to administration.
Vaccinen skal inspiceres visuelt for tilstedeværelsen af partikler og misfarvning forud for indgivelse.
The vaccine should be inspected visually prior to administration for any foreign particulate matter and/or abnormal physical appearance.
Vaccinen skal omrystes omhyggeligt for at opnå en let gennemsigtig hvid suspension før administration.
Before administration, the vaccine should be well shaken to obtain a slightly opaque, white suspension.
Vaccinen skal omrystes omhyggeligt for at opnå en let gennemsigtig hvid suspension og skal inspiceres visuelt for fremmede partikler og/eller unormalt fysisk udseende før administration.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Vaccinen skal omrystes omhyggeligt for at opnå en let gennemsigtig hvid suspension og skal inspiceres visuelt for fremmede partikler og/eller variationer i det fysiske udseende før administration.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration.
Vaccinen skal omrystes omhyggeligt for at opnå en let gennemsigtig, hvid suspension og skal inspiceres visuelt for fremmede partikler og/eller variationer i det fysiske udseende før administration.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration.
Vaccinen skal omrystes omhyggeligt før administration.
The vaccine should be well shaken before use.
Vaccinen skal omrystes omhyggeligt før brug for at opnå en let uigennemsigtig hvid suspension.
Before administration, the vaccine should be well shaken to obtain a slightly opaque, white suspension.
Vaccinen skal omrystes omhyggeligt inden brug for at opnå en let gennemsigtig hvid suspension.
Before administration, the vaccine should be well shaken to obtain a slightly opaque, white suspension.
Vaccinen skal undersøges visuelt for fremmede partikler og/eller usædvanligt udseende.
The vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance.
Vaccinen stimulerer aktiv immunitet mod infektiøs laryngotracheitis og Marek’s disease (smitsom hønselammelse) hos kyllinger.
The vaccine induces active immunity against infectious laryngotracheitis and Marek’s disease in chickens.
Vaccinen stimulerer aktiv immunitet mod infektiøs laryngotracheitis og Marek’s disease hos kyllinger.
The vaccine induces active immunity against infectious laryngotracheitis and Marek’s disease in chickens.
Vaccinen stimulerer aktiv immunitet mod influenza hos hest.
The vaccine stimulates active immunity against equine influenza.
Vaccinen stimulerer aktiv immunitet mod influenza og stivkrampe hos hest.
The vaccine stimulates active immunity against equine influenza and tetanus.
Vaccinen stimulerer udviklingen af et aktivt immunrespons overfor porcint circovirus type 2.
This vaccine is designed to stimulate the development of an active immune response to porcine circovirus type 2.
Vaccinen tilsættes i bufferopløsningen.
Add the vaccine to the buffer solution.